Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hera Therapeutics
Seattle, Washington, United Statesheratherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hera Therapeutics is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of Human Papillomavirus (HPV) infections and associated malignancies. The company's primary research centers on inhibiting the HPV E6 oncoprotein, which is essential for viral persistence and the degradation of the p53 tumor suppressor protein. By targeting this mechanism, Hera aims to develop non-invasive, topical treatments for precancerous lesions such as cervical intraepithelial neoplasia (CIN). Their approach seeks to provide an alternative to surgical interventions, potentially preventing the progression of HPV infections to cervical, anal, and oropharyngeal cancers.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Hera Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hera Therapeutics.